Driving Targeted Protein Degradation Drug Discovery through Biophysical Innovation

What you’ll learn

1. Case studies: practical applications for diverse targets

2. Comprehensive workflows: from binder screening, binary/ternary complex analysis to binding site confirmation, selectivity testing, and off-target profiling

3. Mechanistic insights: how screening strategies differ for Molecular Glues vs. PROTACs

4. Innovation in Action: the Joint Lab’s Biology Building Block concept and its impact on Hit Identification (HitID)

Why attend?

1. Discover how Spectral Shift Assay (SpS) accelerates degrader research

2. Gain actionable insights into designing and screening TPD molecules

3. Learn how the ICE–NanoTemper Joint Lab is setting new benchmarks in induced proximity research

Speakers

Dr. TJ Bing
       Partner / SVP / Head of Biology, ICE Bioscience
       Dr. Bing leads in vitro biology at ICE Bioscience, with extensive experience in target validation, assay development, and HTS in I/O, DDR, GPCR, and PROTAC platforms.

Dr. Thomas Welte
       Senior Application Scientist, NanoTemper Technologies
       Dr. Welte specializes in biophysics and biosensing systems, supporting applications across Northern Europe.